Amplification and/or overexpression of ERBB2, the gene encoding HER2, can be found in
15–20% of invasive breast cancers and is associated with an aggressive phenotype and …

Endocrine therapy (ET) with cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) is currently the
standard first-line treatment for most patients with hormone receptor (HR) positive, human …

Background Outcomes in patients with hormone receptor–positive metastatic breast cancer
worsen after one or more lines of endocrine-based therapy. Trastuzumab deruxtecan has …

The molecular underpinnings of HER2-low and HER2-0 (IHC 0) breast tumors remain poorly
defined. Using genomic findings from 1039 patients with HER2-negative metastatic breast …

Aims With the wide application of trastuzumab deruxtecan (T-DXd), the survival of HER2-low
breast cancer patients is dramatically improved. However, resistance to T-DXd still exists in …

Antibody–drug conjugates (ADC) represent one of the most rapidly expanding treatment
modalities in oncology, with 11 ADCs approved by the FDA and more than 210 currently …

Abstract Patritumab deruxtecan (HER3-DXd) exhibits promising efficacy in breast cancer,
with its activity not directly correlated to baseline ERBB3/HER3 levels. This research …

The integration of cancer biomarkers into oncology has revolutionized cancer treatment,
yielding remarkable advancements in cancer therapeutics and the prognosis of cancer …

Triple-negative breast cancers (TNBCs) are more likely to occur in younger patients and
have a poor prognosis. They are highly heterogeneous tumors consisting of different …

Background Overexpression of human epidermal growth factor receptor 2 (HER2) caused
by HER2 gene amplification is a driver in breast cancer tumorigenesis. We aimed to …